OCTA May Distinguish Familial Exudative Vitreoretinopathy Subtype
New Data on Ranibizumab Biosimilar Demonstrate Noninferiority to Reference Product in DME
Table of Contents
New data presented at the American Academy of Ophthalmology (AAO) 2023 annual meeting reinforce the efficacy and safety of a ranibizumab biosimilar, offering a potentially more affordable treatment option for diabetic macular edema (DME). The study, a phase 3 randomized controlled trial, demonstrated noninferiority to the reference ranibizumab product (Lucentis) in patients with DME.
Study Design and Key Findings
The trial enrolled 300 patients with DME and randomized them 1:1 to receive either the biosimilar or reference ranibizumab. Both groups received intravitreal injections every month for the first 3 months, followed by a treat-and-extend approach based on visual acuity and disease activity.The primary endpoint was the change in best-corrected visual acuity (BCVA) from baseline to month 12. researchers found that the biosimilar arm showed a noninferior change in BCVA compared to the reference product. Specifically, the meen change in BCVA was -0.06 letters in the biosimilar group and -0.08 letters in the reference ranibizumab group, meeting the pre-specified noninferiority margin.
Secondary endpoints, including changes in central retinal thickness (CRT) and proportion of patients gaining ≥15 letters of visual acuity, also favored the biosimilar, though these differences were not statistically significant. Importantly, the safety profiles of both groups were comparable, with similar rates of ocular and systemic adverse events.
implications for Clinical Practice
These findings are encouraging for ophthalmologists and patients alike. DME is a leading cause of vision loss in people with diabetes, and ranibizumab has become a cornerstone of treatment. However, the cost of biologic therapies can be a significant barrier to access.
“The availability of a biosimilar offers the potential to lower treatment costs without compromising efficacy,” explained Dr. Berrocal, lead investigator of the study. “This is particularly critically important for patients who require long-term treatment, as the cumulative cost can be considerable.”
The introduction of biosimilars is expected to increase competition in the market, potentially driving down prices and expanding access to this vital therapy. Biosimilars are not generics; they are highly similar, but not identical, to the reference product. Rigorous regulatory review ensures that biosimilars meet the same standards of safety and efficacy as their reference counterparts.
Future Directions and Considerations
While this study provides strong evidence supporting the use of this ranibizumab biosimilar, ongoing monitoring and real-world data collection will be crucial. Further research is needed to assess the long-term outcomes and cost-effectiveness of biosimilar use in DME.
Ophthalmologists should feel confident in discussing biosimilar options with their patients, explaining the benefits and addressing any concerns.Open dialogue and shared decision-making are essential to ensure optimal patient care.
Berrocal reports no relevant financial disclosures.
Receive an email when new articles are posted on topic.Subscribe
we were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.Back to Healio